La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Chugai Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Chugai Pharmaceutical ha un patrimonio netto totale di ¥1,751.7B e un debito totale di ¥0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente ¥2,060.2B e ¥308.5B. L'EBIT di Chugai Pharmaceutical è ¥486.5B rendendo il suo rapporto di copertura degli interessi 30403.7. Ha liquidità e investimenti a breve termine pari a ¥815.7B.

Informazioni chiave

Rapporto debito/patrimonio netto

JP¥0

Debito

Indice di copertura degli interessi	-203x
Contanti	JP¥815.66b
Patrimonio netto	JP¥1.75t
Totale passività	JP¥308.47b
Totale attività	JP¥2.06t

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Sep 24

Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Jul 30

Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't

Jun 17

Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

May 04

We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

May 01

Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Apr 26

Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected

Mar 01

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥1,476.0B ) di 4519 superano le sue passività a breve termine ( ¥290.1B ).

Passività a lungo termine: Le attività a breve termine di 4519 ( ¥1,476.0B ) superano le sue passività a lungo termine ( ¥18.3B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 4519 è esente da debiti.

Riduzione del debito: 4519 non aveva debiti 5 anni fa.

Copertura del debito: 4519 non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.

Copertura degli interessi: 4519 non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.

Chugai Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Now 20% overvalued after recent price rise

Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Chugai Pharmaceutical (TSE:4519) Is Due To Pay A Dividend Of ¥41.00

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Estimating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)

Upcoming dividend of JP¥41.00 per share

Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00

Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't

Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Final dividend of JP¥41.00 announced

Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected

Price target increased by 7.5% to JP¥5,780

Full year 2023 earnings: EPS exceeds analyst expectations

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024

Upcoming dividend of JP¥40.00 per share at 1.5% yield

Chugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥40.00 per share at 1.9% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Financial Year 2023

Chugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥38.00 per share

Now 21% undervalued

Less than half of directors are independent

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023

Chugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for Full Year of Year Ending December 31, 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Chugai Pharmaceutical Co., Ltd. to Report Q2, 2022 Results on Aug 21, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for first Six Months and Full Year of Year Ending December 2022

Chugai Pharmaceutical Co., Ltd. to Report Nine Months, 2022 Results on Oct 24, 2022

Upcoming dividend of JP¥38.00 per share

Chugai Pharmaceutical Co., Ltd. to Report Q2, 2022 Results on Jul 21, 2022

Less than half of directors are independent

Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year 2022

Chugai Pharmaceutical Co., Ltd. to Report Q1, 2022 Results on Apr 25, 2022

Now 21% undervalued after recent price drop

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 29, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Chugai Pharmaceutical Co., Ltd. Provides End of Fiscal Year Dividend Guidance for the Year Ending December 2022

Upcoming dividend of JP¥30.00 per share

Third quarter 2021 earnings released: EPS JP¥52.32 (vs JP¥36.58 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥43.02 (vs JP¥30.89 in 2Q 2020)

Chugai Pharmaceutical Co., Ltd. Obtains Regulatory Approval from the Ministry of Health, Labour and Welfare for the Anti-SARS-CoV-2 Monoclonal Antibody RONAPREVE

Chugai Pharmaceutical Co., Ltd. Announces That Roche Has Been Granted Marketing Authorization from the European Commission

Upcoming dividend of JP¥30.00 per share

Dividend reduced to JP¥30.00

CHMP Recommends EU Approval of Chugai's Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder

Chugai Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Full Year Ending December 31, 2021

Chugai Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Oct 22, 2021

Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

Chugai Pharmaceutical Co., Ltd. Announces Management Changes

Full year 2020 earnings released: EPS JP¥131 (vs JP¥95.95 in FY 2019)

Revenue beats expectations, earnings disappoint

Chugai Pharmaceutical Co., Ltd Announces Executive Changes

New 90-day high: JP¥5,894

New 90-day high: JP¥5,406

Upcoming Dividend of JP¥25.00 Per Share

New 90-day high: JP¥5,091

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Feb 04, 2021

argenx Announces Partnership with Chugai and the Clayton Foundation

Chugai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 22, 2020

Chugai Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Jul 27, 2020